Hannah Fraser
Biographic Data
| ID | 3863319 |
|---|---|
| NAME | Hannah Fraser |
| GIVEN NAMES | Hannah |
| FAMILY NAME | Fraser |
| SIGNATURE | FRASER H |
| AFFILIATIONS | University of Bristol |
| ORCID | 0000-0003-2443-4463 |
| VERIFIED | Yes |
| TOTAL WORKS | 10 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 10 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2018 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving
INTRODUCTION: UK is one of a few countries that are likely to meet WHO HCV elimination targets of reducing incidence to <2 per 100 person years in People Who Inject Drugs (PWID), but the economic case may be important for investment elsewhere and in future in UK. We illustrate the impact of real-world scaled-up HCV treatment to assess under what drug treatment costs could the investment be cost-saving. METHODS: We utilised a mathematical and econ…
Impact and cost-effectiveness of interventions to eliminate hepatitis C virus among people who inject drugs in Haiphong, Vietnam
Using RDS surveys and other care settings to scale-up HCV-testing and treatment are cost-effective strategies to reduce HCV incidence among PWID in Vietnam
Trends and factors associated with illicit drug use in South Africa
Illicit drug use has increased substantially in South Africa and is associated with numerous socio-demographic characteristics, higher sexual risk behaviours and other well-being variables
Modeling the impact of the Covid-19 pandemic on achieving HCV elimination amongst young and unstably housed people who inject drugs in San Francisco
The COVID-19 pandemic impeded progress toward achieving HCV elimination. Our findings indicate that existing partial rebounds in HCV testing and treatment may achieve the elimination goal by 2030, with an additional scale-up of interventions aimed at YPWID or unstably housed PWID ensuring San Francisco is likely to achieve elimination by 2030
Predicting the replicability of social and behavioural science claims in Covid-19 preprints
Replications are important for assessing the reliability of published findings. However, they are costly, and it is infeasible to replicate everything. Accurate, fast, lower-cost alternatives such as eliciting predictions could accelerate assessment for rapid policy implementation in a crisis and help guide a more efficient allocation of scarce replication resources. We elicited judgements from participants on 100 claims from preprints about an e…
Interventions to prevent HIV and Hepatitis C among people who inject drugs
An intensive model of care for hepatitis C virus screening and treatment with direct‐acting antivirals in people who inject drugs in Nairobi, Kenya
BACKGROUND AND AIMS: Hepatitis C virus (HCV) treatment is essential for eliminating HCV in people who inject drugs (PWID), but has limited coverage in resource-limited settings. We measured the cost-effectiveness of a pilot HCV screening and treatment intervention using directly observed therapy among PWID attending harm reduction services in Nairobi, Kenya. DESIGN: We utilized an existing model of HIV and HCV transmission among current and forme…
Overlapping Key Populations and HIV Transmission in Tijuana, Mexico
Tijuana, Mexico, has a concentrated HIV epidemic among overlapping key populations (KPs) including people who inject drugs (PWID), female sex workers (FSW), their male clients, and men who have sex with men (MSM). We developed a dynamic HIV transmission model among these KPs to determine the extent to which their unmet prevention and treatment needs is driving HIV transmission. Over 2020-2029 we estimated the proportion of new infections acquired…
Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky
Incarceration is likely to be an important contributor to HCV transmission amongst PWID in PC. Prison-based OST could be an important intervention for reducing this risk
Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs
No prominent works on this page.
Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs
An intensive model of care for hepatitis C virus screening and treatment with direct‐acting antivirals in people who inject drugs in Nairobi, Kenya
BACKGROUND AND AIMS: Hepatitis C virus (HCV) treatment is essential for eliminating HCV in people who inject drugs (PWID), but has limited coverage in resource-limited settings. We measured the cost-effectiveness of a pilot HCV screening and treatment intervention using directly observed therapy among PWID attending harm reduction services in Nairobi, Kenya. DESIGN: We utilized an existing model of HIV and HCV transmission among current and forme…
Overlapping Key Populations and HIV Transmission in Tijuana, Mexico
Tijuana, Mexico, has a concentrated HIV epidemic among overlapping key populations (KPs) including people who inject drugs (PWID), female sex workers (FSW), their male clients, and men who have sex with men (MSM). We developed a dynamic HIV transmission model among these KPs to determine the extent to which their unmet prevention and treatment needs is driving HIV transmission. Over 2020-2029 we estimated the proportion of new infections acquired…
Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky
Incarceration is likely to be an important contributor to HCV transmission amongst PWID in PC. Prison-based OST could be an important intervention for reducing this risk
Interventions to prevent HIV and Hepatitis C among people who inject drugs
Trends and factors associated with illicit drug use in South Africa
Illicit drug use has increased substantially in South Africa and is associated with numerous socio-demographic characteristics, higher sexual risk behaviours and other well-being variables
Modeling the impact of the Covid-19 pandemic on achieving HCV elimination amongst young and unstably housed people who inject drugs in San Francisco
The COVID-19 pandemic impeded progress toward achieving HCV elimination. Our findings indicate that existing partial rebounds in HCV testing and treatment may achieve the elimination goal by 2030, with an additional scale-up of interventions aimed at YPWID or unstably housed PWID ensuring San Francisco is likely to achieve elimination by 2030
Predicting the replicability of social and behavioural science claims in Covid-19 preprints
Replications are important for assessing the reliability of published findings. However, they are costly, and it is infeasible to replicate everything. Accurate, fast, lower-cost alternatives such as eliciting predictions could accelerate assessment for rapid policy implementation in a crisis and help guide a more efficient allocation of scarce replication resources. We elicited judgements from participants on 100 claims from preprints about an e…
Impact and cost-effectiveness of interventions to eliminate hepatitis C virus among people who inject drugs in Haiphong, Vietnam
Using RDS surveys and other care settings to scale-up HCV-testing and treatment are cost-effective strategies to reduce HCV incidence among PWID in Vietnam
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving
INTRODUCTION: UK is one of a few countries that are likely to meet WHO HCV elimination targets of reducing incidence to <2 per 100 person years in People Who Inject Drugs (PWID), but the economic case may be important for investment elsewhere and in future in UK. We illustrate the impact of real-world scaled-up HCV treatment to assess under what drug treatment costs could the investment be cost-saving. METHODS: We utilised a mathematical and econ…
HIV, Drug Use, Sexual Risk (7 works) · Medicine (7 works) · Environmental health (6 works) · Hepatitis C virus research (5 works) · HIV/AIDS Research and Interventions (4 works) · Virology (4 works) · Demography (3 works) · Demography (3 works) · Confidence interval (2 works) · Hepatitis B Virus Studies (2 works)